Get the Stockscreener App
0.996
3.26%
0.0314
Tevogen Bio Holdings Inc stock is traded at $0.996, with a volume of 1.38M.
It is up +3.26% in the last 24 hours and down -29.86% over the past month.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes ("CD8+ CTLs" or "CTLs"), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
See More
Previous Close:
$0.9646
Open:
$0.9201
24h Volume:
1.38M
Relative Volume:
0.09
Market Cap:
$174.35M
Revenue:
-
Net Income/Loss:
$-63.55M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-9.56M
1W Performance:
-0.40%
1M Performance:
-29.86%
6M Performance:
+31.92%
1Y Performance:
+0.00%
1-Day Range:
$0.9103
$1.045
1-Week Range:
$0.8565
$1.08
52-Week Range:
$0.2556
$9.51
Tevogen Bio Holdings Inc Stock (TVGN) Company Profile
Name
Tevogen Bio Holdings Inc
Sector
Industry
Phone
646-807-8832
Address
15 INDEPENDENCE BOULEVARD, SUITE 410, WARREN
Compare TVGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVGN
Tevogen Bio Holdings Inc
|
0.996 | 174.35M | 0 | -63.55M | -9.56M | -0.4019 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tevogen Bio Holdings Inc Stock (TVGN) Latest News
Tevogen Bio (TVGN) Advances AI-Driven Immunotherapy with New Patent Filing - Insider Monkey
Tevogen Bio Strengthens Robust IP Portfolio With Filing of - GlobeNewswire
Tevogen Bio Expands AI Drug Discovery Platform with New Patent Filing, Microsoft Partnership - StockTitan
Tevogen Bio Holdings Inc.: Excessive Insider Ownership And Poised For A Seasonal Rebound - Seeking Alpha
TVGNTevogen Bio Holdings Inc. Latest Stock News & Market Updates - StockTitan
Tevogen Bio to Host Panel 'Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Tevogen Bio to Host Panel “Pioneering the Economics of - GlobeNewswire
Tevogen Bio to Host Panel “Pioneering the Economics of Health: Balancing Access and Outcomes” During the 43rd Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Short Interest Up 93.6% in November - MarketBeat
Tevogen Bio to Attend the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Tevogen Bio to Present Off-the-Shelf T Cell Therapeutics at J.P. Morgan Healthcare Conference 2025 - StockTitan
Dr. Ryan Saadi Commends Individuals Who Dedicate Time to Public Service, and Congratulates Mayor Victor Sordillo on His Induction Into the NJ League of Municipalities Hall of Fame - Markets Insider
Tevogen Bio Board Member Honored in NJ League of Municipalities Hall of Fame for Outstanding Service - StockTitan
Tevogen Bio Holdings Inc (TVGN-Q) QuotePress Release - The Globe and Mail
Tevogen Bio (NASDAQ:TVGN) Trading Down 5.6%Time to Sell? - MarketBeat
Tevogen Bio Prepares Organizational Readiness to Support Company's Growth Strategy - The Manila Times
Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy - GlobeNewswire
Tevogen Bio Projects $1B Launch Revenue, Cuts Losses by $52.5M in Strategic Growth Plan | TVGN Stock News - StockTitan
Tevogen Bio CEO Reflects on Public Support, Reaffirms Preserving Shareholder Value Remains His Priority, and Reinforces Options Including a Potential Share Buyback to Support Company Value - The Manila Times
Tevogen Bio CEO Reflects on Public Support, Reaffirms - GlobeNewswire
Tevogen Bio Cuts Q3 Net Loss by $52.5M, Secures 33-Month Runway | TVGN Stock News - StockTitan
Why Keysight Technologies Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Tevogen Bio Holdings Inc. (TVGN) reports earnings - Quartz
Tevogen Bio Reports Third Quarter 2024 Financial Results; Highlights Significantly Improved Financial Position, Unreported Asset Value on Balance Sheets, Efficient Business Model - The Manila Times
Tevogen Bio Reports Third Quarter 2024 Financial Results; - GlobeNewswire
Tevogen Bio Slashes Net Loss by 92%, Secures 33-Month Funding Pipeline | TVGNW Stock News - StockTitan
Tevogen Bio Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Tevogen Bio Slashes Net Loss by 92%, Secures 33-Month Funding Pipeline - StockTitan
Tevogen Founder Reflects on Importance of Preserving Shareholder Value While Navigating Growth as it Prepares to File Quarterly Financials - The Manila Times
UPDATETevogen Founder Reflects on Importance of - GlobeNewswire
Tevogen Bio's Strategic Growth: $40M Spend Yields Robust Pipeline, $200M Warrant Potential | TVGN Stock News - StockTitan
Tevogen Founder Reflects on Importance of Preserving - GlobeNewswire
Tevogen Bio Achieves $40M Cost Efficiency While Building Biotech Portfolio | TVGN Stock News - StockTitan
II: TechBio News Day 👾 - substack.com
Tevogen Bio Shares Are On The Rise Monday: What's Going On? - Benzinga
Tevogen Bio Partners with Microsoft Corporation (MSFT) to Leverage Advanced AI Tools for Biotech Research in Healthcare - Yahoo Finance
Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations - The Manila Times
Tevogen Bio Nears Finalization of Agreement to Enhance R&D - GlobeNewswire
Tevogen Bio Secures $36M Credit Line, Expands Manufacturing With Strategic Deal - StockTitan
Tevogen Bio partners Microsoft for HPV treatment - Yahoo! Voices
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company's Novel Business Model as Key to Sustainable Success through Patient Affordability - The Manila Times
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigio - WICZ
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Company’s Novel Business Model as Key to Sustainable Success through Patient Affordability - GlobeNewswire
Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (HPV), Advancing TVGN 920 - The Manila Times
Tevogen Bio advances HPV oncology treatment TVGN 920 By Investing.com - Investing.com UK
Tevogen Bio Leverages Microsoft Partnership to Deliver Machine L - WICZ
Tevogen Bio Teams with Microsoft AI to Fast-Track HPV Cancer Treatment Development | TVGN Stock News - StockTitan
Tevogen Bio Announces Appointment of Anthony Tarantino as - GlobeNewswire
Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support - Yahoo Finance
Tevogen Bio Holdings Inc. Expands on Microsoft Partnership to Integrate Machine Learning and AI into Preclinical Processes, Accelerating Drug Development and Reducing Costs - Marketscreener.com
Tevogen partners with Microsoft to speed up drug development By Investing.com - Investing.com Australia
Tevogen Bio Holdings Inc Stock (TVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tevogen Bio Holdings Inc Stock (TVGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Desai Kirti | Chief Financial Officer |
Jun 12 '24 |
Buy |
0.82 |
3,000 |
2,460 |
9,699,186 |
| Saadi Ryan H. | Chief Executive Officer |
Jun 05 '24 |
Buy |
0.77 |
2,607 |
2,000 |
118,252,659 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):